151 related articles for article (PubMed ID: 27898660)
1. Asthma and risk of myelodysplastic syndromes: a population-based cohort study.
Frederiksen H; Farkas DK; Horváth-Puhó E; Nørgaard JM; Nørgaard M; Sørensen HT
Br J Cancer; 2017 Jan; 116(1):100-102. PubMed ID: 27898660
[TBL] [Abstract][Full Text] [Related]
2. The use of medical claims to assess incidence, diagnostic procedures and initial treatment of myelodysplastic syndromes and chronic myelomonocytic leukemia in the Netherlands.
Dinmohamed AG; van Norden Y; Visser O; Posthuma EF; Huijgens PC; Sonneveld P; van de Loosdrecht AA; Jongen-Lavrencic M
Leuk Res; 2015 Feb; 39(2):177-82. PubMed ID: 25533930
[TBL] [Abstract][Full Text] [Related]
3. Vasculitis associated with myelodysplastic syndrome and chronic myelomonocytic leukemia: French multicenter case-control study.
Roupie AL; Guedon A; Terrier B; Lahuna C; Jachiet V; Regent A; de Boysson H; Carrat F; Seguier J; Terriou L; Versini M; Queyrel V; Groh M; Benhamou Y; Maurier F; Ledoult E; Clech LL; D'Aveni M; Rossignol J; Galland J; Willems L; Chiche NJ; Peterlin P; Roux-Sauvat M; Parcelier A; Wemeau M; Lambert M; Belizna C; Puechal X; Swiader L; Cohen-Valensi R; Noc V; Dao E; Thepot S; de Frémont GM; Tanguy-Schmidt A; Koka AM; Bussone G; Philipponnet C; Konate A; Cavaille G; Guilpain P; Allain JS; Broner J; Solary E; Ruivard M; de Renzis B; Corm S; Baati N; Schleinitz N; Ponsoye M; Stamatoullas-Bastard A; Ades L; Dellal A; Tchirkov A; Aouba A; Fenaux P; Fain O; Mekinian A;
Semin Arthritis Rheum; 2020 Oct; 50(5):879-884. PubMed ID: 32896704
[TBL] [Abstract][Full Text] [Related]
4. Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme.
van der Helm LH; Alhan C; Wijermans PW; van Marwijk Kooy M; Schaafsma R; Biemond BJ; Beeker A; Hoogendoorn M; van Rees BP; de Weerdt O; Wegman J; Libourel WJ; Luykx-de Bakker SA; Minnema MC; Brouwer RE; Croon-de Boer F; Eefting M; Jie KS; van de Loosdrecht AA; Koedam J; Veeger NJ; Vellenga E; Huls G
Br J Haematol; 2011 Dec; 155(5):599-606. PubMed ID: 21981697
[TBL] [Abstract][Full Text] [Related]
5. Venous thromboembolism during systemic inflammatory and autoimmune diseases associated with myelodysplastic syndromes, chronic myelomonocytic leukaemia and myelodysplastic/myeloproliferative neoplasms: a French multicentre retrospective case-control study.
Péan de Ponfilly-Sotier M; Jachiet V; Benhamou Y; Lahuna C; De Renzis B; Kottler D; Voillat L; Dimicoli-Salazar S; Banos A; Chauveheid MP; Alexandra JF; Grignano E; Liferman F; Laborde M; Broner J; Michel M; Lambotte O; Laribi K; Venon MD; Dussol B; Martis N; Thepot S; Park S; Couret D; Roux-Sauvat M; Terriou L; Hachulla E; Bally C; Galland J; Allain JS; Parcelier A; Peterlin P; Cohen-Bittan J; Regent A; Ackermann F; Le Guen J; Algrin C; Charles P; Daguindau E; Puechal X; Dunogue B; Blanchard-Delaunay C; Beyne-Rauzy O; Grobost V; Schmidt J; Le Gallou T; Dubos-Lascu G; Sonet A; Denis G; Roy-Peaud F; Fenaux P; Adès L; Fain O; Mekinian A;
Clin Exp Rheumatol; 2022 Jul; 40(7):1336-1342. PubMed ID: 35579092
[TBL] [Abstract][Full Text] [Related]
6. Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure.
Harel S; Cherait A; Berthon C; Willekens C; Park S; Rigal M; Brechignac S; Thépot S; Quesnel B; Gardin C; Adès L; Fenaux P; Braun T
Leuk Res; 2015 May; 39(5):501-4. PubMed ID: 25735917
[TBL] [Abstract][Full Text] [Related]
7. Real-world data of MDS and CMML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11).
Usuki K; Ohtake S; Honda S; Matsuda M; Wakita A; Nawa Y; Takase K; Maeda A; Sezaki N; Yokoyama H; Takada S; Hirano D; Tomikawa T; Sumi M; Yano S; Handa H; Ota S; Fujita H; Fujimaki K; Mugitani A; Kojima K; Kajiguchi T; Fujimoto K; Asou N; Usui N; Ishikawa Y; Katsumi A; Matsumura I; Miyazaki Y; Kiyoi H
Int J Hematol; 2024 Feb; 119(2):130-145. PubMed ID: 38091231
[TBL] [Abstract][Full Text] [Related]
8. [Clinical features of a new category, myelodysplastic/myeloproliferative diseases, defined by WHO classification].
Fukuhara T; Kakinoki Y
Rinsho Byori; 2006 Mar; 54(3):243-9. PubMed ID: 16637572
[TBL] [Abstract][Full Text] [Related]
9. Red blood cell alloimmunization in transfused patients with myelodysplastic syndrome or chronic myelomonocytic leukemia.
Sanz C; Nomdedeu M; Belkaid M; Martinez I; Nomdedeu B; Pereira A
Transfusion; 2013 Apr; 53(4):710-5. PubMed ID: 22845746
[TBL] [Abstract][Full Text] [Related]
10. [Significance and application value of multiparameter flow cytometry for differentiation of immunophenotype in chronic myelomonocytic leukemia, myelodysplastic syndrome and acute monocytic leukemia].
Wang YX; Zhang JH; Hu YP; Cao FF; Zhang N; Chen F; Liu X; Zhang MY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Aug; 20(4):857-62. PubMed ID: 22931642
[TBL] [Abstract][Full Text] [Related]
11. Autoimmune disorders are common in myelodysplastic syndrome patients and confer an adverse impact on outcomes.
Montoro J; Gallur L; Merchán B; Molero A; Roldán E; Martínez-Valle F; Villacampa G; Navarrete M; Ortega M; Castellví J; Saumell S; Bobillo S; Bosch F; Valcárcel D
Ann Hematol; 2018 Aug; 97(8):1349-1356. PubMed ID: 29572561
[TBL] [Abstract][Full Text] [Related]
12. The incidence of myelodysplastic syndromes in Western Greece is increasing.
Avgerinou C; Alamanos Y; Zikos P; Lampropoulou P; Melachrinou M; Labropoulou V; Tavernarakis I; Aktypi A; Kaiafas P; Raptis C; Kouraklis A; Karakantza M; Symeonidis A
Ann Hematol; 2013 Jul; 92(7):877-87. PubMed ID: 23572136
[TBL] [Abstract][Full Text] [Related]
13. MDS/CMML from resource-limited region: Characteristics and comparison to tertiary reference European center.
Sevoyan A; Mekinian A; Chermat F; Adès L; Ivanyan A; Fenaux P; Hakobyan Y
Eur J Haematol; 2024 Feb; 112(2):296-300. PubMed ID: 37822035
[TBL] [Abstract][Full Text] [Related]
14. Immunophenotype in chronic myelomonocytic leukemia: is it closer to myelodysplastic syndromes or to myeloproliferative disorders?
Subirá D; Font P; Villalón L; Serrano C; Askari E; Góngora E; Castañón S; Gonzalo R; Mata R; Román A; Llamas P
Transl Res; 2008 May; 151(5):240-5. PubMed ID: 18433705
[TBL] [Abstract][Full Text] [Related]
15. Cutting the cord from myelodysplastic syndromes: chronic myelomonocytic leukemia-specific biology and management strategies.
Padron E; Steensma DP
Curr Opin Hematol; 2015 Mar; 22(2):163-70. PubMed ID: 25575034
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of azacitidine in Belgian patients with high-risk myelodysplastic syndromes, acute myeloid leukaemia, or chronic myelomonocytic leukaemia: results of a real-life, non-interventional post-marketing survey.
Beguin Y; Selleslag D; Meers S; Graux C; Bries G; Deeren D; Vrelust I; Ravoet C; Theunissen K; Voelter V; Potier H; Trullemans F; Noens L; Mineur P
Acta Clin Belg; 2015 Feb; 70(1):34-43. PubMed ID: 25444072
[TBL] [Abstract][Full Text] [Related]
17. Targeted Next-Generation Sequencing in Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia Aids Diagnosis in Challenging Cases and Identifies Frequent Spliceosome Mutations in Transformed Acute Myeloid Leukemia.
Reinig E; Yang F; Traer E; Arora R; Brown S; Rattray R; Braziel R; Fan G; Press R; Dunlap J
Am J Clin Pathol; 2016 Apr; 145(4):497-506. PubMed ID: 27124934
[TBL] [Abstract][Full Text] [Related]
18. Survivin expression, apoptosis and proliferation in chronic myelomonocytic leukemia.
Invernizzi R; Travaglino E; Benatti C; Malcovati L; Della Porta M; Cazzola M; Ascari E
Eur J Haematol; 2006 Jun; 76(6):494-501. PubMed ID: 16529600
[TBL] [Abstract][Full Text] [Related]
19. [Evolutive epidemiologic profile of myelodysplastic syndromes (1959-1993). Comparative study with acute myeloid leukemia and aplastic pancytopenias].
Sánchez Fayos J; Outeiriño Pérez JJ; Prieto E; Román A; Olavarría E; Cabello A; Soto C; Calabuig T; Paniagua C; Sanz B
Sangre (Barc); 1994 Dec; 39(6):441-8. PubMed ID: 7855696
[TBL] [Abstract][Full Text] [Related]
20. Results of topotecan-based combination therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia.
Beran M; Kantarjian H
Semin Hematol; 1999 Oct; 36(4 Suppl 8):3-10. PubMed ID: 10622223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]